Literature DB >> 7901169

Latency is not an inevitable outcome of infection with Pneumocystis carinii.

W Chen1, F Gigliotti, A G Harmsen.   

Abstract

Severe combined immunodeficiency (SCID) mice resolve naturally acquired Pneumocystis carinii pneumonia after reconstitution with immunocompetent spleen cells and can therefore be used as a model to study latent P. carinii infection. Neither P. carinii nor amplified P. carinii DNA was detected in the lungs of SCID mice killed 21 days after spleen cell reconstitution. Furthermore, SCID mice that recovered from P. carinii infection failed to reactivate the infection after they were either depleted of CD4+ cells for up to 84 days or depleted of CD4+ cells and treated with corticosteroid for 35 days. These results indicate that an immune response to P. carinii can completely clear the organism from the host. This supports the hypothesis that P. carinii pneumonia that develops in immunocompromised patients may be a new infection resulting from exposure to an exogenous source of P. carinii and not necessarily from reactivation of latent infection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7901169      PMCID: PMC281332          DOI: 10.1128/iai.61.12.5406-5409.1993

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  23 in total

1.  Latent Pneumocystis infection of rats, relapse, and chemotherapy.

Authors:  J K Frenkel; J T Good; J A Shultz
Journal:  Lab Invest       Date:  1966-10       Impact factor: 5.662

2.  A natural source of infection due to pneumocystis carinii.

Authors:  W T Hughes; D L Bartley; B M Smith
Journal:  J Infect Dis       Date:  1983-03       Impact factor: 5.226

3.  A new model of Pneumocystis carinii infection in mice selectively depleted of helper T lymphocytes.

Authors:  J Shellito; V V Suzara; W Blumenfeld; J M Beck; H J Steger; T H Ermak
Journal:  J Clin Invest       Date:  1990-05       Impact factor: 14.808

4.  Observations favouring Pneumocystis carinii pneumonia as a primary infection: a monoclonal antibody study on paraffin sections.

Authors:  P R Millard; A R Heryet
Journal:  J Pathol       Date:  1988-04       Impact factor: 7.996

5.  Natural mode of acquisition for de novo infection with Pneumocystis carinii.

Authors:  W T Hughes
Journal:  J Infect Dis       Date:  1982-06       Impact factor: 5.226

6.  DNA amplification in experimental pneumocystosis: characterization of serum Pneumocystis carinii DNA and potential P. carinii carrier states.

Authors:  K Sepkowitz; N Schluger; T Godwin; D Armstrong; A Cerami; R Bucala
Journal:  J Infect Dis       Date:  1993-08       Impact factor: 5.226

7.  Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children.

Authors:  L L Pifer; W T Hughes; S Stagno; D Woods
Journal:  Pediatrics       Date:  1978-01       Impact factor: 7.124

8.  Experimental Pneumocystis carinii pneumonia in the ferret.

Authors:  D C Stokes; F Gigliotti; J E Rehg; R L Snellgrove; W T Hughes
Journal:  Br J Exp Pathol       Date:  1987-04

9.  Detection of Pneumocystis carinii with DNA amplification.

Authors:  A E Wakefield; F J Pixley; S Banerji; K Sinclair; R F Miller; E R Moxon; J M Hopkin
Journal:  Lancet       Date:  1990-08-25       Impact factor: 79.321

10.  Requirement for CD4+ cells in resistance to Pneumocystis carinii pneumonia in mice.

Authors:  A G Harmsen; M Stankiewicz
Journal:  J Exp Med       Date:  1990-09-01       Impact factor: 14.307

View more
  26 in total

1.  Magnetic bead capture eliminates PCR inhibitors in samples collected from the airborne environment, permitting detection of Pneumocystis carinii DNA.

Authors:  N Maher; H K Dillon; S H Vermund; T R Unnasch
Journal:  Appl Environ Microbiol       Date:  2001-01       Impact factor: 4.792

Review 2.  Extrapulmonary pneumocystosis.

Authors:  V L Ng; D M Yajko; W K Hadley
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

Review 3.  New advances in understanding the host immune response to Pneumocystis.

Authors:  J Claire Hoving; Jay K Kolls
Journal:  Curr Opin Microbiol       Date:  2017-11-12       Impact factor: 7.934

4.  Immune-mediated inflammation directly impairs pulmonary function, contributing to the pathogenesis of Pneumocystis carinii pneumonia.

Authors:  T W Wright; F Gigliotti; J N Finkelstein; J T McBride; C L An; A G Harmsen
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

5.  Study of internal transcribed spacer and mitochondrial large-subunit genes of Pneumocystis carinii hominis isolated by repeated bronchoalveolar lavage from human immunodeficiency virus-infected patients during one or several episodes of pneumonia.

Authors:  S Latouche; J L Poirot; C Bernard; P Roux
Journal:  J Clin Microbiol       Date:  1997-07       Impact factor: 5.948

Review 6.  Pneumocystis carinii: what is it, exactly?

Authors:  J R Stringer
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

7.  Usefulness of PCR for diagnosis of Pneumocystis carinii pneumonia in different patient groups.

Authors:  M Weig; H Klinker; B H Bögner; A Meier; U Gross
Journal:  J Clin Microbiol       Date:  1997-06       Impact factor: 5.948

8.  Development and evaluation of a molecular viability assay for Pneumocystis carinii.

Authors:  N Maher; S Vermund; M Lasbury; C Lee; M Bartlett; T R Unnasch
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

9.  Sequences of Pneumocystis carinii f. sp. hominis strains associated with recurrent pneumonia vary at multiple loci.

Authors:  S P Keely; J R Stringer
Journal:  J Clin Microbiol       Date:  1997-11       Impact factor: 5.948

10.  Active immunity to Pneumocystis carinii reinfection in T-cell-depleted mice.

Authors:  A G Harmsen; W Chen; F Gigliotti
Journal:  Infect Immun       Date:  1995-07       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.